These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1114 related articles for article (PubMed ID: 2510580)

  • 41. Evaluation of Mannich bases of styryl ketones and related hydrazones for activity against P388 leukemia.
    Dimmock JR; Jonnalagadda SS; Leek DM; Warrington RC; Fang WD
    Neoplasma; 1988; 35(6):715-24. PubMed ID: 3221938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones.
    Kuśnierczyk H; Chołody WM; Paradziej-Lukowicz J; Radzikowski C; Konopa J
    Arch Immunol Ther Exp (Warsz); 1994; 42(5-6):415-23. PubMed ID: 8572901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mitomycin C analogues with increased metal complexing ability.
    Iyengar BS; Sami SM; Takahashi T; Sikorski EE; Remers WA; Bradner WT
    J Med Chem; 1986 Sep; 29(9):1760-4. PubMed ID: 3091833
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
    Li LH; Wallace TL; Richard KA; Tracey DE
    Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stability of the in vivo P388 leukemia model in evaluation of antitumor activity of natural products.
    Marsh JC; Shoemaker RH; Suffness M
    Cancer Treat Rep; 1985 Jun; 69(6):683-5. PubMed ID: 4016772
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic characteristics and antitumor activity of the N-succinyl-chitosan-mitomycin C conjugate and the carboxymethyl-chitin-mitomycin C conjugate.
    Song Y; Onishi H; Nagai T
    Biol Pharm Bull; 1993 Jan; 16(1):48-54. PubMed ID: 8369752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C.
    Kobayashi E; Okabe M; Kono M; Arai H; Kasai M; Gomi K; Lee JH; Inaba M; Tsuruo T
    Cancer Chemother Pharmacol; 1993; 32(1):20-4. PubMed ID: 8096440
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New potent mitomycin derivatives: synthesis and antitumor activity of 7,7-(ethylenedioxy)mitomycins.
    Kanda Y; Arai H; Ashizawa T; Morimoto M; Kasai M
    J Med Chem; 1992 Jul; 35(15):2781-6. PubMed ID: 1495011
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vivo drug release and antitumor characteristics of water-soluble conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan.
    Sato M; Onishi H; Takahara J; Machida Y; Nagai T
    Biol Pharm Bull; 1996 Sep; 19(9):1170-7. PubMed ID: 8889036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The action of 7-N-(p-hydroxyphenyl)mitomycin C [M-83] in suppressing murine immune response.
    Okabe M; Imai R; Morimoto M
    J Antibiot (Tokyo); 1982 Aug; 35(8):1055-62. PubMed ID: 6754673
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nucleotide derivatives of 2,7-diaminomitosene.
    Iyengar BS; Dorr RT; Remers WA; Kowal CD
    J Med Chem; 1988 Aug; 31(8):1579-85. PubMed ID: 3397995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo properties of the conjugates of mitomycin C with estradiol benzoate and estradiol: pharmacokinetics and antitumor characteristics against P388 leukemia and sarcoma 180.
    Ishiki N; Onishi H; Machida Y
    Biol Pharm Bull; 1998 Nov; 21(11):1180-6. PubMed ID: 9853409
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel antitumor cyclic hexapeptide (RA-700) obtained from Rubiae radix.
    Hamanaka T; Ohgoshi M; Kawahara K; Yamakawa K; Tsuruo T; Tsukagoshi S
    J Pharmacobiodyn; 1987 Nov; 10(11):616-23. PubMed ID: 3128656
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the hematologic toxicity of 7-N-(p-hydroxyphenyl),-mitomycin C and mitomycin C.
    Kobayashi T; Inaba M; Tsukagoshi S; Sakurai Y; Imai R; Morimoto M
    Gan; 1981 Dec; 72(6):950-4. PubMed ID: 6804297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and antitumor activity of a novel water soluble mitomycin analog; 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C.
    Kono M; Saitoh Y; Kasai M; Sato A; Shirahata K; Morimoto M; Ashizawa T
    Chem Pharm Bull (Tokyo); 1989 Apr; 37(4):1128-30. PubMed ID: 2766417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative antitumor activities of 7-N-(p-hydroxyphenyl)mitomycin C (M-83) and mitomycin C.
    Imai R; Morimoto M
    J Antibiot (Tokyo); 1983 May; 36(5):559-65. PubMed ID: 6409871
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metal complexes of mitomycins.
    Iyengar BS; Takahashi T; Remers WA; Bradner WT
    J Med Chem; 1986 Jan; 29(1):144-7. PubMed ID: 3079830
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of new mitomycin C and porfiromycin analogues.
    Iyengar BS; Lin HJ; Cheng L; Remers WA; Bradner WT
    J Med Chem; 1981 Aug; 24(8):975-81. PubMed ID: 7328599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potentiation of mitomycin C cytotoxicity by glutathione depletion in a multi-drug resistant mouse leukemia cell line.
    Xu BH; Singh SV
    Cancer Lett; 1992 Sep; 66(1):49-53. PubMed ID: 1451095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.